Published in Mol Cancer on October 05, 2012
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175
PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol (2015) 1.24
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Emerging targeted therapies for melanoma treatment (review). Int J Oncol (2014) 1.10
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Semin Oncol (2015) 0.85
Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol (2014) 0.85
TAK1 inhibition-induced RIP1-dependent apoptosis in murine macrophages relies on constitutive TNF-α signaling and ROS production. J Biomed Sci (2015) 0.78
Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. Onco Targets Ther (2013) 0.77
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. J Transl Med (2015) 0.77
In Vitro Antiproliferative Activity of Extracts of Carlina acaulis subsp. caulescens and Carlina acanthifolia subsp. utzka. Front Pharmacol (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Integrating signals from RTKs to ERK/MAPK. Oncogene (2007) 3.28
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res (2010) 2.90
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest (2005) 2.62
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31
Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol (2009) 2.27
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther (2012) 2.21
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest (2008) 2.17
Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res (2007) 2.15
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One (2009) 2.07
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res (2008) 1.87
Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene (2004) 1.83
Regulation of the PTEN phosphatase. Gene (2006) 1.69
Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer (2009) 1.60
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer (2007) 1.57
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res (2008) 1.52
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol (2007) 1.49
p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther (2004) 1.40
A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia (2009) 1.23
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol (2011) 1.20
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med (2008) 1.13
Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther (2006) 1.10
Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys (2005) 1.08
CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res (1997) 1.07
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res (2010) 1.07
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res (2009) 1.06
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res (2009) 1.02
Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III. Bioorg Med Chem Lett (2010) 0.95
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer (2011) 0.88
Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol (2007) 6.67
Transcriptional profile of aging in C. elegans. Curr Biol (2002) 3.02
The genome of the fire ant Solenopsis invicta. Proc Natl Acad Sci U S A (2011) 2.74
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res (2005) 2.27
Does gum chewing ameliorate postoperative ileus? Results of a prospective, randomized, placebo-controlled trial. J Am Coll Surg (2006) 2.19
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res (2008) 1.87
Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene (2004) 1.83
Generation and dynamics of an endogenous, self-generated signaling gradient across a migrating tissue. Cell (2013) 1.62
Deceased-donor kidney transplantation: improvement in long-term survival. Nephrol Dial Transplant (2010) 1.60
Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. Circ Cardiovasc Interv (2012) 1.52
Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med (2011) 1.51
Robotic-assisted laparoscopic radical prostatectomy: learning curve of first 100 cases. Int J Urol (2010) 1.49
Templated nanocrystal-based porous TiO(2) films for next-generation electrochemical capacitors. J Am Chem Soc (2009) 1.47
Ordered mesoporous alpha-MoO3 with iso-oriented nanocrystalline walls for thin-film pseudocapacitors. Nat Mater (2010) 1.46
FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One (2012) 1.45
Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res (2010) 1.44
Surgically curable non-iron deficiency microcytic anemia: Castleman's disease. Onkologie (2011) 1.44
Impact of severe oesophagogastric varices on liver resection for hepatocellular carcinoma in cirrhotic patients. World J Surg (2015) 1.41
p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther (2004) 1.40
Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem (2007) 1.39
Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res (2009) 1.36
Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest (2013) 1.32
Overexpression of activation-induced cytidine deaminase in B cells is associated with production of highly pathogenic autoantibodies. J Immunol (2007) 1.30
Pseudocapacitive contributions to charge storage in highly ordered mesoporous group V transition metal oxides with iso-oriented layered nanocrystalline domains. J Am Chem Soc (2010) 1.29
A crystallographic snapshot of tyrosine trans-phosphorylation in action. Proc Natl Acad Sci U S A (2008) 1.25
Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res (2007) 1.23
Cocaine hijacks σ1 receptor to initiate induction of activated leukocyte cell adhesion molecule: implication for increased monocyte adhesion and migration in the CNS. J Neurosci (2011) 1.21
Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res (2011) 1.21
p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res (2010) 1.21
Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Mol Cancer Res (2009) 1.18
The learning curve for reducing complications of robotic-assisted laparoscopic radical prostatectomy by a single surgeon. BJU Int (2010) 1.17
Central neurocytoma: a clinical, radiological and pathological study of nine cases. Clin Neurol Neurosurg (2007) 1.15
Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res (2009) 1.14
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci (2014) 1.13
Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status. Ann Surg Oncol (2008) 1.13
Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol (2007) 1.10
A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res (2011) 1.09
The double-histone-acetyltransferase complex ATAC is essential for mammalian development. Mol Cell Biol (2008) 1.09
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. Hum Pathol (2009) 1.08
Investigations into the regulation and function of the SH2 domain-containing protein-tyrosine phosphatase, SHP-1. Immunol Res (2006) 1.08
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol (2010) 1.06
Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clin Cancer Res (2011) 1.05
Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. Anticancer Res (2012) 1.02
Overexpression of 14-3-3ε predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology (2011) 1.01
14-3-3ε overexpression contributes to epithelial-mesenchymal transition of hepatocellular carcinoma. PLoS One (2013) 1.00
Tidal volume and respiratory timing derived from a portable ventilation monitor. Chest (2002) 1.00
Fourmidable: a database for ant genomics. BMC Genomics (2009) 0.99
The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg (2003) 0.99
Synchronous gastric gastrointestinal stromal tumor and signet-ring cell adenocarcinoma: a case report. Int J Surg Pathol (2007) 0.99
Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells. J Immunol (2006) 0.98
Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. J Biol Chem (2011) 0.97
Intrarenal color duplex ultrasonography: a window to vascular complications of renal transplants. J Ultrasound Med (2007) 0.97
Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment. Oncotarget (2014) 0.96
Combined primary neuroendocrine carcinoma and hepatocellular carcinoma of the liver. J Chin Med Assoc (2009) 0.96
FGFR2 as a molecular target in endometrial cancer. Future Oncol (2009) 0.96
Lucky draw in the gene raffle. Nature (2002) 0.96
Intrinsically fluorescent carbon dots with tunable emission derived from hydrothermal treatment of glucose in the presence of monopotassium phosphate. Chem Commun (Camb) (2011) 0.95
FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol (2010) 0.95
Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Mol Cell Biol (2009) 0.94
Cocaine and HIV-1 interplay: molecular mechanisms of action and addiction. J Neuroimmune Pharmacol (2011) 0.93
Hyaluronan modulates accumulation of hypoxia-inducible factor-1 alpha, inducible nitric oxide synthase, and matrix metalloproteinase-3 in the synovium of rat adjuvant-induced arthritis model. Arthritis Res Ther (2011) 0.93
Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms. Curr HIV Res (2012) 0.93
Changes in reproductive roles are associated with changes in gene expression in fire ant queens. Mol Ecol (2010) 0.92
Ordered mesoporous α-Fe2O3 (hematite) thin-film electrodes for application in high rate rechargeable lithium batteries. Small (2010) 0.92
Primary appendiceal precursor B lymphoblastic lymphoma with peculiar morphology mimicking diffuse large B cell lymphoma. Pathol Int (2010) 0.92
3,3'-Difluoro-4,4'-(p-phenyl-enedi-oxy)dibenzonitrile. Acta Crystallogr Sect E Struct Rep Online (2009) 0.91
Comparison of robotic-assisted versus retropubic radical prostatectomy performed by a single surgeon. Anticancer Res (2009) 0.91
Increased expression of 14-3-3β promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. Am J Pathol (2011) 0.91
Involvement of 14-3-3γ overexpression in extrahepatic metastasis of hepatocellular carcinoma. Hum Pathol (2010) 0.91
In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res (2007) 0.91
Arugosins G and H: prenylated polyketides from the marine-derived fungus Emericellanidulans var. acristata. J Nat Prod (2006) 0.90
Hepatic adenomatosis associated with hormone replacement therapy and hemosiderosis: a case report. World J Gastroenterol (2006) 0.90
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia (2013) 0.90
Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. Cancer Sci (2011) 0.89
Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk. Hum Reprod (2008) 0.89
Downstream targets of let-60 Ras in Caenorhabditis elegans. Dev Biol (2002) 0.88
Spinal atypical teratoid/rhabdoid tumor in a 7-year-old boy. Neuropathology (2007) 0.88
Monotypic epithelioid angiomyolipoma of the liver with TFE3 expression. Pathology (2010) 0.88
The critical role of Fas-Fas ligand interaction in donor-specific transfusion-induced tolerance to H-Y antigen. Transplantation (2004) 0.88
Notch and NOXA-related pathways in melanoma cells. J Investig Dermatol Symp Proc (2005) 0.87
Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. J Transl Med (2012) 0.87
Synchronous renal cell carcinoma and clear cell hepatocellular carcinoma mimicking metastatic disease. Pathol Res Pract (2009) 0.87
Mutual ferromagnetic-ferroelectric coupling in multiferroic copper-doped ZnO. Adv Mater (2011) 0.86
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anticancer Drugs (2013) 0.86
Intrahepatic biliary cysts in biliary atresia in the era of liver transplantation. J Pediatr Gastroenterol Nutr (2003) 0.86
Ferroelectric behavior in bismuth ferrite thin films of different thickness. ACS Appl Mater Interfaces (2011) 0.86
Osteosarcoma arising in a long-standing uterine leiomyoma: a case report and literature review. Int J Surg Pathol (2008) 0.85
Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy. Neurotox Res (2013) 0.85
Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. Mol Ther (2008) 0.85
Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma. Anticancer Agents Med Chem (2013) 0.85
Thyroid involvement in Rosai-Dorfman disease. Thyroid (2007) 0.85
A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP). J Biomol Screen (2002) 0.85